Global LFA-based Cardiac Market Growth (Status and Outlook) 2023-2029

Global LFA-based Cardiac Market Growth (Status and Outlook) 2023-2029

Lateral Flow Assay is a simple to use diagnostic device used to confirm the presence or absence of a target analyte, such as pathogens or biomarkers in humans or animals, or contaminants in water supplies, foodstuffs, or animal feeds.
Cardiac biomarkers are the substances released into the blood stream from the damaged muscle of the heart. These biomarkers are used to diagnose heart functioning, risk stratifications, and cardiac diseases in patients. Biomarker is a quantifiable and measurable biological parameter that includes an enzyme, hormones, and proteins, all associated with heart function, failure, or damage.
LPI (LP Information)' newest research report, the “LFA-based Cardiac Industry Forecast” looks at past sales and reviews total world LFA-based Cardiac sales in 2022, providing a comprehensive analysis by region and market sector of projected LFA-based Cardiac sales for 2023 through 2029. With LFA-based Cardiac sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world LFA-based Cardiac industry.
This Insight Report provides a comprehensive analysis of the global LFA-based Cardiac landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on LFA-based Cardiac portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global LFA-based Cardiac market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for LFA-based Cardiac and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global LFA-based Cardiac.
The global LFA-based Cardiac market size is projected to grow from US$ 3517.2 million in 2022 to US$ 6104.6 million in 2029; it is expected to grow at a CAGR of 8.2% from 2023 to 2029.
The industry's leading producers are Roche, Abbott and Siemens, with revenues of 26.24%, 16.11% and 11.04% respectively in 2019.
This report presents a comprehensive overview, market shares, and growth opportunities of LFA-based Cardiac market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Troponin I
Troponin T
CK-MB
Myoglobin
Others
Segmentation by application
Laboratory Testing
Point-of-care Testing
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Roche
Abbott
Siemens
Danaher
Bio-Rad Laboratories
BioMérieux
Thermo Fisher
Ortho Clinical Diagnostics
LSI Medience Corporation
Randox laboratories
Wondfo Biotech

Please note: The report will take approximately 2 business days to prepare and deliver.